FDAsafety guidance77% confidence
FDA AP — MORPHINE SULFATE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hikma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA022207. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: MORPHINE SULFATE.
Supporting Context
- Therapeutic area
- Oncology · Supportive Care
- Sub-indication
- General
Related signal: Hikma's Leucovorin Calcium ANDA072736 Receives AP Status from FDA